A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed NSCLC * Advanced NSCLC * Measurable disease (as defined by Response Evaluation Criteria in Solid Tumors \[RECIST 1.0\]) * Eastern Cooperative Oncology Group (ECOG) Performance Status is ≤ 1 * Age ≥ 18 years * Adequate hematologic function = an absolute neutrophil count (ANC) ≥ 1500/μL, hemoglobin ≥ 9 g/dL, and a platelet count ≥ 100,000/microliter (μL) * Adequate hepatic function = a total bilirubin ≤ 1.5 mg/dL transaminases and alkaline phosphatase ≤ 5 x the upper limit of normal (ULN) * Adequate renal function serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance (CrCl) \> 60 mL/minute, and urine dipstick for protein \< 1+ (ie, either 0 or trace) * Adequate coagulation function, INR ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 5 seconds above ULN * Adequate contraception * Signed informed consent Exclusion Criteria: * Untreated CNS metastases * Prior bevacizumab therapy * Radiologically documented evidence of major blood vessel invasion or encasement by cancer * Prior systemic chemotherapy for Stage IIIB/IV NSCLC * Prior systemic chemotherapy or radiation therapy for Stage I-IIIA NSCLC \< 1 year prior * Any concurrent malignancy other than basal cell skin cancer, or carcinoma in situ of the cervix * Concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy * Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Uncontrolled thrombotic or hemorrhagic disorders * Poorly-controlled hypertension * Chronic daily treatment with aspirin (\> 325 mg/day) or other known inhibitors of platelet function * History of gross hemoptysis (defined as bright red blood or ≥ 1/2 teaspoon) * Serious non-healing wound, ulcer, or bone fracture * Undergone major surgery or subcutaneous venous access device placement. Post-operative bleeding complications or wound complications from a surgical procedures performed in the last 2 months * Elective or a planned major surgery to be performed during the course of the trial * Peripheral neuropathy ≥ Grade 2 (National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 3.0 \[NCI-CTCAE v 3.0\]) * If female, is pregnant or lactating * Radiographic evidence of intratumor cavitation * Grade 3-4 gastrointestinal bleeding within 3 months prior to study entry